{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:43:50Z","timestamp":1789685030833,"version":"4.0.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Institut de Recherche en Sant\u00e9 Respiratoire des Pays de la Loire"},{"name":"Ligue Contre le Cancer Grand Ouest"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12943-018-0891-0","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T06:36:33Z","timestamp":1539239793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis"],"prefix":"10.1186","volume":"17","author":[{"given":"Patrick","family":"Smeele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e8nan Micka\u00ebl","family":"d\u2019Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Meiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Ch\u00e9n\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Liddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Cellerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Benziane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Copin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Le Pimpec-Barthes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Porte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0917-3747","authenticated-orcid":false,"given":"Christophe","family":"Blanquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"891_CR2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.21037\/atm.2017.06.60","volume":"5","author":"HH Sun","year":"2017","unstructured":"Sun HH, Vaynblat A, Pass HI. Diagnosis and prognosis-review of biomarkers for mesothelioma. Ann Transl Med. 2017;5:244.","journal-title":"Ann Transl Med"},{"key":"891_CR3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","volume":"178","author":"F Gueugnon","year":"2011","unstructured":"Gueugnon F, Leclercq S, Blanquart C, Sagan C, Cellerin L, Padieu M, et al. Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol. 2011;178:1033\u201342.","journal-title":"Am J Pathol"},{"key":"891_CR4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3892\/etm.2011.302","volume":"2","author":"BC Duysinx","year":"2011","unstructured":"Duysinx BC, Paulus A, Heinen V, Nguyen D, Henket M, Corhay JL, et al. Diagnostic value of neurotrophin expression in malignant pleural effusions. Exp Ther Med. 2011;2:941\u20136.","journal-title":"Exp Ther Med"},{"key":"891_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cccn.2004.10.002","volume":"352","author":"WA Nockher","year":"2005","unstructured":"Nockher WA, Renz H. Neurotrophins in clinical diagnostics: pathophysiology and laboratory investigation. Clin Chim Acta. 2005;352:49\u201374.","journal-title":"Clin Chim Acta"},{"key":"891_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1183\/09031936.00226111","volume":"41","author":"I Pantazopoulos","year":"2013","unstructured":"Pantazopoulos I, Boura P, Xanthos T, Syrigos K. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J. 2013;41:706\u201315.","journal-title":"Eur Respir J"},{"key":"891_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/08977191003677402","volume":"28","author":"A Ricci","year":"2010","unstructured":"Ricci A, Mariotta S, Pompili E, Mancini R, Bronzetti E, De Vitis C, et al. Neurotrophin system activation in pleural effusions. Growth Factors. 2010;28:221\u201331.","journal-title":"Growth Factors"},{"key":"891_CR8","first-page":"3983","volume":"37","author":"DP Radin","year":"2017","unstructured":"Radin DP, Patel P. BDNF: an oncogene or tumor suppressor? Anticancer Res. 2017;37:3983\u201390.","journal-title":"Anticancer Res"},{"key":"891_CR9","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1002\/jcb.25943","volume":"118","author":"A Tajbakhsh","year":"2017","unstructured":"Tajbakhsh A, Mokhtari-Zaer A, Rezaee M, Afzaljavan F, Rivandi M, Hassanian SM, et al. Therapeutic potentials of BDNF\/TrkB in breast Cancer; current status and perspectives. J Cell Biochem. 2017;118:2502\u201315.","journal-title":"J Cell Biochem"},{"key":"891_CR10","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin cisplatin Pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-018-0891-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-018-0891-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-018-0891-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T19:21:21Z","timestamp":1570735281000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-018-0891-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1186\/s12943-018-0891-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]},"assertion":[{"value":"30 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All recruited patients gave signed, informed consent. All the collected samples and the associated clinical information were registered in database (DC-2011-1399 and DC-2013-1963) validated by the French research ministry.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"148"}}